#12: NewsBot: BMY News United Devices Chosen By Bristol-Myers Squibb For Replacement of Cluster, Grid Infrastructure
AUSTIN, Texas--(BUSINESS WIRE)--United Devices (UD) said today that Bristol-Myers... |
March 20, 2007
07:08:00 AM |
#11: NewsBot: BMY News Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds
PRINCETON, N.J. & WALTHAM, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company... |
February 26, 2007
05:00:00 AM |
#10: NewsBot: BMY News Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
PRINCETON, N.J. & FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J.--(BUSINESS... |
October 8, 2006
11:30:00 PM |
#9: NewsBot: BMY News Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb... |
September 28, 2006
04:57:00 PM |
#8: NewsBot: BMY News L’administration américaine des denrées et des médicaments (FDA) approuve l'ATRIPLA(TM) (éfavirenz 600 mg/ emtricitabine 200 mg/ fumarate de ténofovir disoproxil 300 mg) ...
PRINCETON, New Jersey et FOSTER CITY, Californie--(BUSINESS WIRE)--15 juillet... |
July 14, 2006
10:08:00 PM |
#7: NewsBot: BMY News US-Arzneimittelzulassungsbehörde FDA genehmigt ATRIPLA(TM) (Efavirenz 600 mg/ Emtricitabin 200 mg/ Tenofovir Disoproxil Fumarat 300 mg), die erste Therapie in Form einer einzigen einmal täglich einzunehmenden Tablette für Erwachsene mit...
PRINCETON, US-Bundesstaat New Jersey, und FOSTER CITY, US-Bundesstaat... |
July 14, 2006
09:47:00 AM |
#6: NewsBot: BMY News Riassunto: L’ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) approva ATRIPLA(TM) (efavirenz 600 mg/ emtricitabina 200 mg/ tenofovir disoproxil fumarato 300 mg)
PRINCETON, New Jersey, e FOSTER CITY, California--(BUSINESS WIRE)--12 luglio... |
July 12, 2006
05:17:00 PM |
#3: NewsBot: BMY News Resumen: La Agencia de Alimentos y Fármacos de EE.UU. (FDA) aprueba ATRIPLA(TM) (efavirenz 600 mg/ emtricitabina 200 mg/ fumarato de tenofovir 300 mg), el primer tratamiento de una sola dosis diaria para adultos infectados por HIV-1
PRINCETON, Nueva Jersey y FOSTER CITY, California--(BUSINESS WIRE)--12 julio,... |
July 12, 2006
10:52:00 AM |
#4: NewsBot: BMY News Samenvatting: Amerikaanse Food and Drug Administration keurt Atripla, de eerste één-dagelijkse tablet voor volwassenen met HIV-1 infectie, goed
PRINCETON, New Jersey en FOSTER CITY, Californië--(BUSINESS WIRE)--12 juli,... |
July 12, 2006
10:52:00 AM |
#5: NewsBot: BMY News U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
PRINCETON, N.J. and FOSTER CITY, Calif.--(BUSINESS WIRE)--July 12, 2006-- ... |
July 12, 2006
10:52:00 AM |
#2: NewsBot: BMY News FDA Accepts ERBITUX(R) (Cetuximab) sBLA Submission for the Treatment of Squamous Cell Carcinoma of the Head and Neck and Grants Priority Review
NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Oct. 31, 2005--ImClone Systems... |
October 31, 2005
01:00:00 AM |
#1: NewsBot: BMY News Survey Provides Insights Into Factors Influencing Drug Adherence Among HIV Patients
--(BUSINESS WIRE)--According to a national survey of people living with HIV/AIDS,... |
October 17, 2005
10:01:00 PM |
| 
| 
| 
| 
| 
| 
